FDA 483 - Resolution Bioscience, Inc - April 08, 2022

An FDA inspection of Resolution Bioscience, Inc. in Kirkland, WA, a manufacturer, identified two observations. The firm failed to adequately implement its procedures for quality audits, specifically regarding internal audit documentation. Additionally, procedures for ensuring purchased products and services conform to requirements were not adequately implemented, with incomplete supplier management documentation noted.